EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance

Maria Apostolopoulou, Vaia Lambadiari iD, Michael Roden iD, George D Dimitriadis

Endocrine Reviews · 09.05.2025 · 46 (3) · 317-348

DOI: 10.1210/endrev/bnae032 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine Reviews, online erschienen am 25.02.2025. Verfasst von Maria Apostolopoulou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine University, 40225 Düsseldorf, Germany. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Resistance, Hypoglycemic Agents. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 388 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

People with type 1 diabetes (T1D) are usually considered to exclusively exhibit β-cell failure, but they frequently also feature insulin resistance. This review discusses the mechanisms, clinical features, and therapeutic relevance of insulin resistance by focusing mainly on human studies using gold-standard techniques (euglycemic–hyperinsulinemic clamp). In T1D, tissue-specific insulin resistance can develop early and sustain throughout disease progression. The underlying pathophysiology is complex, involving both metabolic- and autoimmune-related factors operating synergistically. Insulin treatment may play an important pathogenic role in predisposing individuals with T1D to insulin resistance. However, the established lifestyle-related risk factors and peripheral insulin administration inducing glucolipotoxicity, hyperinsulinemia, hyperglucagonemia, inflammation, mitochondrial abnormalities, and oxidative stress cannot always fully explain insulin resistance in T1D, suggesting a phenotype distinct from type 2 diabetes. The mutual interaction between insulin resistance and impaired endothelial function further contributes to diabetes-related complications. Insulin resistance should therefore be considered a treatment target in T1D. Aside from lifestyle modifications, continuous subcutaneous insulin infusion can ameliorate insulin resistance and hyperinsulinemia, thereby improving glucose toxicity compared with multiple injection insulin treatment. Among other concepts, metformin, pioglitazone, incretin-based drugs such as GLP-1 receptor agonists, sodium-glucose cotransporter inhibitors, and pramlintide can improve insulin resistance, either directly or indirectly. However, considering the current issues of high cost, side effects, limited efficacy, and their off-label status, these agents in people with T1D are not widely used in routine clinical care at present.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Insulin ResistanceHypoglycemic AgentsHumansInsulin

Stichwörter der Autor:innen

diabetes therapyglucotoxicity/lipotoxicityinsulin resistancetype 1 diabetesvascular dysfunction

Substanzen

Hypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine University, 40225 Düsseldorf, Germany.
  • Institute for Clinical Diabetology, German Diabetes Center, Leibnitz Center for Diabetes Research at Heinrich-Heine University, 40225 Düsseldorf, Germany.
  • German Center of Diabetes Research (DZD), Partner Düsseldorf, 85764 München-Neuherberg, Germany.
  • 2nd Department of Internal Medicine, Research Institute and Diabetes Center, National and Kapodistrian University of Athens Medical School, 12462 Athens, Greece.

ORCID-Profile: Vaia Lambadiari, Michael Roden

Zitieren

APA

Apostolopoulou, M., Lambadiari, V., Roden, M., & Dimitriadis, G. D. (2025). Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance. Endocrine Reviews, 46(3), 317-348. https://doi.org/10.1210/endrev/bnae032

Vancouver

Apostolopoulou M, Lambadiari V, Roden M, Dimitriadis GD. Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance. Endocrine Reviews. 2025;46(3):317-348. doi:10.1210/endrev/bnae032

BibTeX
@article{Apostolopoulou2025,
  author = {Apostolopoulou, Maria and Lambadiari, Vaia and Roden, Michael and Dimitriadis, George D},
  title = {Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance},
  journal = {Endocrine Reviews},
  year = {2025},
  volume = {46},
  number = {3},
  pages = {317--348},
  doi = {10.1210/endrev/bnae032}
}
Kostenlos starten →